Platelet-Rich Plasma Injection for Knee Osteoarthritis by KL Grade in 2026

Introduction: Why “Does PRP Work?” Is the Wrong Question

Most people researching platelet-rich plasma (PRP) for knee osteoarthritis (OA) have moved past the basic question of whether the treatment exists or is worth considering. They have usually tried physical therapy, anti-inflammatory medications, or a corticosteroid injection, and they want to know something more specific: Is PRP likely to work for a knee like mine?

That question rarely gets a direct answer. Much of the content online treats PRP as a single treatment with a single outcome, either “it works” or “it doesn’t.” This framing hides an important fact. Knee OA outcomes vary widely depending on how advanced the disease is. A patient with early cartilage wear and a patient with bone-on-bone arthritis are not candidates for the same expectations, even if they receive the same injection.

The missing variable is the Kellgren-Lawrence (KL) grade, the radiographic scale clinicians use to stage knee OA. When research results are sorted by KL grade, a much clearer picture appears.

This article breaks down PRP outcomes grade by grade using the most current 2026 evidence. It covers the major guideline disagreement between the American Academy of Physical Medicine & Rehabilitation (AAPM&R) and the American College of Rheumatology (ACR), and it closes with a practical next step for each grade. It is a framework for a conversation with a qualified provider, not a replacement for imaging and clinical evaluation.

Understanding the Kellgren-Lawrence (KL) Grading System

The KL system is a 0 to 4 scale based on X-ray findings. It rates features such as osteophytes (bone spurs), joint space narrowing, bony sclerosis, and deformity. A higher grade indicates more advanced structural damage.

Clinical studies rely on KL grade rather than symptoms alone because pain levels can be misleading. Two people with similar pain may have very different amounts of remaining cartilage, and remaining cartilage strongly influences how well a regenerative injection can perform. That is why researchers increasingly report PRP outcomes stratified by grade.

This issue affects a large population. Global prevalence of knee OA among adults 40 and older is approximately 22.9%, and more than 32 million U.S. adults live with osteoarthritis. Global Burden of Disease modeling projects knee OA incidence will rise 33.6% and prevalence 43.8% by 2035.

KL Grade 0: Normal Joint

Grade 0 means there is no radiographic evidence of osteoarthritis. PRP is not indicated at this stage because there is no degenerative target for the injection to address.

If a patient has knee pain with a Grade 0 X-ray, the pain likely comes from another source, such as a meniscus tear, tendinopathy, ligament injury, patellofemoral dysfunction, or an inflammatory condition. The appropriate pathway is further diagnostic workup, which may include MRI or ultrasound, rather than injection therapy for OA.

KL Grade 1: Doubtful Narrowing, Possible Osteophyte Lipping

Grade 1 shows subtle findings: possible small osteophytes with no definite joint space narrowing. These are the earliest radiographic signs of OA.

Evidence suggests this group represents the best-case responder profile. A 113-patient prospective cohort of KL Grade 1 and 2 patients found that Grade 1 patients showed greater improvement than Grade 2 patients at every follow-up point. Better results were strongly linked to younger age and lower radiographic grade.

There is a caveat. Because OA is radiographically minimal at Grade 1, some patients may be borderline candidates. Standard candidacy criteria call for exhausting conservative care first, including physical therapy, activity modification, weight management, and appropriate medications, before moving to injection therapy.

KL Grade 2: Definite Osteophytes, Possible Narrowing

Grade 2 is classic “mild OA,” with definite osteophytes and possible mild joint space narrowing. This range has some of the most consistent supporting data:

• A large 2025 Japanese real-world cohort found no significant differences in pain improvement among KL Grades 1 through 3, suggesting consistent benefit across this range.
• A study of high-dose neutrophil-depleted PRP in 212 patients with KL Grades 1 to 3 reported OMERACT-OARSI responder rates of 68.9% at 3 months, 72.7% at 6 months, and 70.6% at 12 months.
• Mayo Clinic reports a 60% to 70% chance of success, defined as at least a 50% improvement in pain and function lasting 6 to 12 months. This serves as a reasonable benchmark for patients in this grade range.

Grade 2 sits squarely within the population the 2026 AAPM&R guidance most strongly supports.

KL Grade 3: Multiple Osteophytes, Definite Narrowing, Sclerosis

Grade 3 represents “moderate OA,” with multiple osteophytes, definite joint space narrowing, and bony sclerosis. Many patients assume this level of damage rules out PRP, but the evidence suggests otherwise.

The same Japanese cohort found no significant difference in pain improvement between Grade 3 and Grades 1 to 2. A 2026 narrative review on optimizing PRP outcomes reached a similar conclusion: PRP is effective across KL grades, with the greatest benefits in early to moderate OA, and knees with KL Grades 1 through 3 consistently experience meaningful and sustained clinical improvement. Response begins to taper only at Grade 4.

Grade 3 is also where combination approaches become more relevant. A 2025 meta-analysis of randomized controlled trials found PRP produced superior functional improvement compared with hyaluronic acid (HA), especially when PRP and HA were combined.

Grade 3 marks the upper boundary of the AAPM&R “mild-to-moderate” recommendation window.

KL Grade 4: Severe Narrowing, Large Osteophytes, Deformity

Grade 4 is severe, often called “bone-on-bone,” OA. It features severe joint space narrowing, large osteophytes, marked sclerosis, and frequently visible deformity.

The evidence here calls for realistic expectations:

• A prospective, blinded, placebo-controlled study in KL Grade 4 patients who were not candidates for joint replacement found that serial PRP injections produced only mild, short-term improvement. Results met minimal clinically important difference thresholds and outperformed saline on WOMAC and VAS scores, but absolute gains were modest.
• The Japanese real-world cohort found that Grade 4 showed significantly less improvement than Grades 2 and 3.

PRP can still provide measurable relief at this stage, but that relief tends to be smaller and shorter-lived. It is most relevant for patients who are not surgical candidates or who want to delay surgery. Grade 4 is also where guideline disagreement is sharpest, and where combination biologics or alternative non-surgical interventions deserve serious consideration.

The 2026 Guideline Conflict: AAPM&R vs. ACR vs. AAOS

In 2026, major medical societies disagree openly about PRP for knee OA. This is a legitimate, unresolved clinical debate, and patients deserve an honest account of it.

Conflicting guidelines can coexist because societies apply different evidence thresholds, weigh certainty ratings differently, and approach treatment with different clinical philosophies. Some evaluate whether a therapy helps the average patient across a broad population, while others ask whether it helps well-selected patients under well-defined protocols.

AAPM&R’s Pro-PRP Guidance (April 2026)

In April 2026, AAPM&R published a guidance statement developed by a technical expert panel. It recommends considering PRP for patients with mild-to-moderate knee OA who remain symptomatic despite conservative care. The expert consensus also indicated that earlier intervention leads to better outcomes, which aligns with the grade-based pattern described above.

The guidance also addressed PRP formulation. It concluded that leukocyte concentration does not play a significant role in patient-reported outcomes. Leukocyte-poor PRP (LP-PRP) ranked statistically higher than leukocyte-rich PRP by SUCRA ranking, but the panel noted the difference may not be clinically important.

ACR’s Strong Recommendation Against PRP (2026)

The 2026 updated ACR osteoarthritis guideline takes the opposite position. It strongly recommends against PRP and stem cell injections for knee and hip OA.

A critical nuance often goes unmentioned: the ACR rated the certainty of the evidence behind this recommendation as low. A strong recommendation based on low-certainty evidence reflects a conservative, population-level standard. The ACR asks whether evidence is robust enough to endorse a therapy broadly, while AAPM&R focuses on patient selection, disease stage, and preparation protocol.

Where AAOS and Other Societies Stand

The American Academy of Orthopaedic Surgeons (AAOS) occupies middle ground. Its clinical practice guideline states PRP may reduce pain and improve function in symptomatic knee OA, with a strength of recommendation rated “Limited.”

Other groups, including OARSI and the French Society of Rheumatology, have historically opposed PRP or remained neutral.

The practical takeaway is that no single authority has the final word in 2026. Patients are best served by weighing grade-specific evidence and discussing it with a provider rather than relying on any one guideline alone.

What Else Influences PRP Outcomes Within Each Grade

KL grade is the primary predictor of PRP response, but it is not the only one. Protocol quality varies significantly between providers, and several variables affect results.

Platelet Dose and Concentration

Not all PRP contains the same number of platelets. A systematic review and meta-analysis identified an optimal threshold of greater than 10 billion platelets for favorable functional outcomes in knee OA, with a stronger effect on function than on pain.

A separate 2026 meta-analysis complicated that picture. It found platelet counts between 5 and 10 billion were associated with the largest effect size for function, while very high doses did not necessarily outperform moderate doses for pain.

The research has not settled on a single ideal number, but both analyses agree that dose matters. Patients should ask providers how their PRP is prepared and whether the platelet dose is measured.

Leukocyte-Rich vs. Leukocyte-Poor PRP

Clinic marketing sometimes claims one formulation is dramatically superior. The evidence does not support that claim. A network meta-analysis found no statistically significant difference between LP-PRP and L-PRP in direct comparison. Both formulations were significantly superior to placebo and to hyaluronic acid for functional improvement.

Combined with the AAPM&R finding, the conclusion is clear: leukocyte content is a minor variable compared with disease stage and platelet dose.

Age, Conservative Care History, and Joint Condition

In the KL Grade 1 to 2 cohort, younger age and lower radiographic grade were strongly associated with better outcomes. Commonly cited candidacy criteria include:

• KL Grade 1 to 3 OA with cartilage still present
• Age roughly 40 to 70
• Documented failure of conservative care (physical therapy, NSAIDs, weight management) for at least 2 to 4 months
• A goal of delaying or avoiding surgery

These criteria are general guardrails, not guarantees. Individual imaging and clinical evaluation remain necessary.

PRP in Context: How It Compares to Other Treatment Options

PRP is one option among several, and understanding where it fits helps patients make better decisions.

PRP vs. Corticosteroid Injections

Mayo Clinic physicians note that steroid injections sometimes work faster, often within the first 4 to 6 weeks, but PRP typically outperforms steroids by 3 to 6 months after treatment. This trade-off matters for patients weighing quick short-term relief against longer-lasting benefit.

PRP vs. Hyaluronic Acid (HA)

A 2025 meta-analysis of 28 RCTs involving 3,246 patients found PRP delivered comparable pain relief to HA but superior functional improvement, with added benefit when the two were combined. That combination is particularly relevant for Grade 3 patients.

A separate 2025 meta-analysis of six RCTs with 1,162 mild-to-moderate knee OA patients, using OMERACT-OARSI responder criteria, confirmed PRP’s pain and function benefits against HA, corticosteroid, and placebo comparators. PRP also outperformed physical and exercise therapy in pain and function.

PRP vs. Bone Marrow Aspirate Concentrate (BMAC)

Comparisons between PRP and BMAC are mixed. Some studies show BMAC produces greater improvement in VAS, KOOS, and WOMAC scores. Others, including a three-study synthesis in KL Grade 2 to 4 patients, found no statistically significant difference.

A larger systematic review of 27 Level I studies (1,042 PRP patients and 226 BMAC patients) found both PRP and BMAC outperformed HA, with no significant difference between the two.

BMAC is a reasonable alternative or complementary biologic to discuss in consultation, particularly for Grade 3 and 4 patients seeking a more robust option.

Your Next Step by KL Grade: A Decision Framework

The evidence translates into a practical action plan for each grade:

• Grade 0: PRP is not indicated. Further diagnostic evaluation is the appropriate next step to identify a non-OA cause of pain.
• Grade 1 to 2: Strong PRP candidacy, assuming conservative care has been tried. The next step is a consultation for an imaging-confirmed diagnosis and a personalized protocol.
• Grade 3: Good candidacy. PRP alone or combined with hyaluronic acid may enhance functional outcomes. A consultation is the appropriate next step.
• Grade 4: Modest, shorter-term benefit is realistic. Patients may consider PRP combined with another biologic such as BMAC, or explore other non-surgical options, especially if they are not arthroplasty candidates.

Across every actionable grade, imaging-guided delivery and individualized platelet dosing meaningfully affect real-world results.

Safety, Candidacy, and What to Expect From Treatment

Common contraindications include:

• Active local or systemic infection
• Bleeding or platelet disorders
• Anticoagulant therapy that cannot be safely paused
• Anemia
• Pregnancy
• Active malignancy
• Severe joint deformity or instability

Expected side effects are usually mild. Localized soreness, stiffness, and a temporary flare of swelling or pain in the first 48 to 72 hours are common and considered part of the normal inflammatory healing response. Serious adverse events are rare. Mayo Clinic has treated more than 1,100 knee OA patients with PRP with no serious adverse events.

Typical protocols involve 1 to 3 injections spaced 1 to 6 weeks apart, adjusted to the patient’s grade, symptoms, and response.

Regulatory status: PRP is regulated by the FDA’s Center for Biologics Evaluation and Research (CBER) under 21 CFR 1271. Minimally manipulated, autologous PRP used in the same procedure on the same patient is generally exempt from biologics licensing under the Same Surgical Procedure Exception. The devices and kits used to prepare PRP are regulated separately and often carry 510(k) clearance, which addresses device safety rather than efficacy for a specific condition.

Insurance: Most insurers, including Medicare, do not cover PRP for knee OA. Patients should confirm coverage and payment structure directly with their provider.

Conclusion: Letting Your KL Grade Guide an Informed Decision

PRP is not a uniform treatment with a single predictable outcome. Its value depends on disease stage, protocol quality, and individual patient factors.

The 2026 guideline landscape is genuinely divided. AAPM&R supports considering PRP for mild-to-moderate OA, while ACR strongly recommends against it based on low-certainty evidence, and AAOS sits in between. Informed patients benefit from weighing grade-specific evidence rather than deferring to a single authority.

The overall spectrum is consistent across studies: the strongest and most consistent benefit appears in KL Grades 1 through 3, modest and shorter-term benefit appears in KL Grade 4, and PRP has no role at KL Grade 0. This framework is best used as the starting point for a conversation with a qualified provider who can confirm KL grade with imaging and tailor a protocol accordingly.

Get an Imaging-Confirmed, Personalized PRP Evaluation at Unicorn Bioscience

Unicorn Bioscience builds its knee OA care around the variables the research identifies as most important. Every injection is delivered with ultrasound or X-ray guidance, supporting accurate placement into the target joint, and treatment protocols are developed for the individual rather than applied uniformly.

For patients with more advanced disease, the clinic’s multi-modal approach is especially relevant. Alongside PRP, Unicorn Bioscience offers BMAC, hyaluronic acid injections, exosome therapy, stem cell therapy, and peptide therapy, allowing combination strategies for Grade 3 and Grade 4 knees when appropriate.

Treatment plans are personalized based on inflammation levels, age, injury type and location, current medications, and personal goals, which are the same patient factors linked to PRP outcomes in clinical studies. Consistent with its commitment to transparency, the clinic notes that as of 2026 the FDA has not approved PRP, stem cell, or exosome products specifically for orthopedic conditions, and all treatments are administered in the United States within FDA regulatory frameworks.

Qualified candidates may receive same-day treatment, and both virtual and in-person consultations are available across 8 locations in Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, Boca Raton, and Manhattan.

Patients can schedule a consultation to confirm their KL grade and candidacy and determine whether PRP alone or a combined regenerative protocol is the right next step.

• Phone: (737) 347-0446
• Website: unicornbioscience.com